Latest Breaking News On - Pmmr mss serous endometrial cancer - Page 1 : comparemela.com

Mirvetuximab soravtansine plus pembrolizumab in patients with recurrent or persistent, FRalpha-positive, pMMR/MSS serous endometrial cancer, according to findings from a phase 2 trial.

United statesRebeccal porterGynecologic oncology programDana farber cancer instituteDana farber cancer institutePmmr mss serous endometrial cancerPhase 2 trial nct03835819Mirvetuximab soravtansine elahere and pembrolizumab keytruda